What is the Wolverine Blend? BPC-157 & TB-500 Explained

Compound Spotlight

The Wolverine Blend pairs BPC-157 and TB-500, the two most widely discussed compounds in tissue-repair research. Both have extensive preclinical literature, complementary proposed mechanisms, and — this is the part usually omitted — almost no controlled human evidence between them. This article covers both compounds properly, including why the evidence gap exists.

BPC-157

BPC-157 is a pentadecapeptide — fifteen amino acids — corresponding to a partial sequence of a larger protein identified in human gastric juice and designated Body Protection Compound. Its most distinctive chemical property is stability: it resists degradation in gastric acid, which is unusual for a peptide and is why gastrointestinal research on it has been feasible.

Proposed mechanisms

Unlike most compounds in this catalog, BPC-157 has no single identified receptor. The literature describes several converging pathways instead. It is reported to upregulate VEGF receptor 2 signaling, promoting angiogenesis — new blood vessel formation, which is a prerequisite for repair in poorly vascularized tissue like tendon. It is described as modulating the nitric oxide system, and as influencing focal adhesion kinase (FAK) and paxillin signaling, which coordinate cell adhesion and migration during wound closure.

The angiogenesis mechanism deserves a caveat that is rarely stated. Promoting new blood vessel growth is exactly what makes a compound plausible for tissue repair, and also the reason its long-term effects in the presence of undiagnosed malignancy are an open question. Tumors depend on angiogenesis. Whether this represents a real risk in humans is genuinely unknown, and “unknown” is the accurate word rather than “safe.”

The evidence problem

Two structural issues run through the BPC-157 literature.

The first is concentration of authorship. The great majority of the several hundred published BPC-157 studies originate from the group led by Predrag Sikirić at the University of Zagreb, which has worked on the compound since the 1990s. The work is peer-reviewed and internally consistent, and some findings have been confirmed elsewhere, but broad independent replication is limited. As with any striking result, independent reproduction is what converts a finding into an established one.

The second is the near-absence of human trials. Despite an enormous animal literature spanning gastric ulcers, tendon transection, ligament injury, colitis, and nerve injury, published human data consists of a small number of uncontrolled pilot studies with very few participants in total — no randomized controlled trials, no placebo arms. A Phase I study registered years ago was reportedly cancelled without publishing results.

There is a plausible and non-conspiratorial explanation for the gap: the peptide sequence itself is difficult to protect with the kind of exclusivity that justifies the cost of clinical development. Without patent protection, no company has an economic reason to spend heavily on trials only to face immediate generic competition. This is a recognized structural failure in drug development for off-patent molecules, and it explains the evidence vacuum better than any claim about suppression.

Regulatory position

BPC-157 is not approved for human therapeutic use by the FDA, the EMA, or any other regulator. WADA added it to the Prohibited List in 2022 under category S0 (non-approved substances). In 2023 the FDA designated it a Category 2 bulk drug substance, citing concerns including immunogenicity and peptide-related manufacturing impurities, which excludes it from compounding. Reclassification has been petitioned and the matter has been subject to ongoing review — anyone who needs the current position should verify it directly with FDA sources rather than relying on secondary summaries.

TB-500

TB-500 is frequently described as “synthetic Thymosin Beta-4.” That is not accurate, and the distinction matters.

Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein and the primary actin-sequestering molecule in mammalian cells. TB-500 is a short synthetic fragment of it, corresponding to the actin-binding domain (the LKKTETQ region). It reproduces one functional domain of the parent protein, not the whole molecule — much as AOD-9604 reproduces one domain of growth hormone.

Actin, and why it matters for repair

Actin is the cytoskeletal protein that cells use to change shape and move. Cell migration — fibroblasts entering a wound bed, endothelial cells forming new vessels, keratinocytes closing an epithelial gap — requires continuous, controlled assembly and disassembly of actin filaments.

Tβ4 binds monomeric actin and maintains a reserve pool available for rapid filament assembly. The proposed rationale for TB-500 is that supplying this actin-binding activity supports the cell migration that tissue repair depends on. Related research directions include angiogenesis, inflammation modulation, and reduced fibrosis.

Notably, full-length Tβ4 — not TB-500 — has been taken into human clinical trials, including work on corneal wound healing and dry eye disease. That means the parent protein has more human evaluation behind it than the fragment being sold, which is worth knowing when reading claims that transfer Tβ4 findings onto TB-500.

Why the two are combined

The stated rationale is mechanistic complementarity: BPC-157 associated with vascular supply and growth-factor signaling, TB-500 with cell mobility. Repair plausibly requires both — blood supply to deliver materials, and cells able to migrate to where they are needed.

That is a coherent hypothesis. It should be read as a hypothesis: there is no controlled research demonstrating that the combination outperforms either compound alone, and combination effects cannot be assumed from separate single-compound data.

Frequently asked questions

Is TB-500 the same as Thymosin Beta-4?

No. Tβ4 is a 43-amino-acid protein; TB-500 is a short synthetic fragment representing its actin-binding domain. Research findings on one should not be assumed to apply to the other.

Why does BPC-157 have so little human data?

Largely economics. The sequence is hard to protect with strong patent exclusivity, so no sponsor has a commercial incentive to fund expensive trials. The result is hundreds of animal studies and essentially no controlled human evidence.

Does combining them work better?

Unknown. The complementary-mechanism rationale is reasonable but has not been tested in controlled research. No study has compared the combination against either compound individually.

How do I know what is actually in the vial?

Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.

References

• Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2018;16(7):1049–1062.
• Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159.
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429.
• Józwiak M, et al. BPC-157: literature and patent review. Pharmaceuticals (Basel). 2025.

View the Wolverine Blend product listing →

Read our KLOW Blend breakdown →

Look up your lot Certificate of Analysis →

For laboratory and research use only. Not for human consumption. Neither BPC-157 nor TB-500 is approved by any regulatory authority, and BPC-157 is prohibited by WADA. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.

Related research compounds

Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:

• Wolverine (BPC-157 & TB-500)
• BPC-157
• TB-500

For laboratory research use only. Not for human consumption.